The link between inflammation and cancer was famously proposed by Rudolf Virchow in 1863 after he observed leucocytes within neoplastic tissues, but an appreciation of the association was first documented by the ancient Greek physician Galen. However almost 160 years post-Virchov, the precise nature of the relationship remains incompletely understood and there are currently no drugs targeting inflammation in cancer. Glantaf Biofarma has identified a natural molecule that inhibits a critical pathway related to inflammation and demonstrated that that this pathway is key in the progression of cancer. Furthermore, Glantaf has created intellectual property by using a novel, globally patented nano-formulating process to create the lead molecule Glan-001. The company is currently in the process of raising finances to conduct pre-clinical studies and take Glan-001 through to investigational new drug status, and onwards through clinic trial to patients. The initial target for Glan-001 is pancreatic cancer, a tumor where inflammation plays an important role, and so should benefit from this new and novel approach. Pancreatic cancer is an unmet need. It is currently the 10th most common cancer in the UK and the 5th most common cause of cancer-related death. The incidence of pancreatic cancer is in excess of 10,000 cases, and this is predicted to double by 2030. The overall 5-year survival of patients is 10%, the main reason for this being that at presentation, 50% will have metastatic disease. Only 10% of are suitable for potentially curative therapy while another 10% may become candidates with the aid of chemotherapy and radiotherapy prior to an operation. However, even with optimal therapy, the 5-year survival is only in the order of 30%. There is therefore a critical need for more effective therapies to treat all stages of the disease.